{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:19:31Z","timestamp":1794277171683,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1038\/s41591-024-03037-z","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T13:02:26Z","timestamp":1717419746000},"page":"2224-2234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":242,"title":["Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9157-3768","authenticated-orcid":false,"given":"Changsong","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9388-4180","authenticated-orcid":false,"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-8600","authenticated-orcid":false,"given":"Yanshuo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-6279","authenticated-orcid":false,"given":"Jiajia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-3255","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6936-2622","authenticated-orcid":false,"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"3037_CR1","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. & Fry, T. J. Mechanisms of resistance to CAR T cell therapy. Nat. Rev. Clin. Oncol. 16, 372\u2013385 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3037_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick, K., O\u2019Brien, S., Moon, E. & Albelda, S. M. CAR T cell therapy for solid tumors. Annu. Rev. Med. 68, 139\u2013152 (2017).","journal-title":"Annu. Rev. Med."},{"key":"3037_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47\u201366 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3037_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","volume":"18","author":"J Wei","year":"2021","unstructured":"Wei, J. et al. Clinical development of CAR T cell therapy in China: 2020 update. Cell. Mol. Immunol. 18, 792\u2013804 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"3037_CR5","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","volume":"4","author":"C Global Burden of Disease Cancer","year":"2018","unstructured":"Global Burden of Disease Cancer, C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease study. JAMA Oncol. 4, 1553\u20131568 (2018).","journal-title":"JAMA Oncol."},{"key":"3037_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3037_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota, Y. et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8, 100762 (2023).","journal-title":"ESMO Open"},{"key":"3037_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.21147\/j.issn.1000-9604.2024.01.08","volume":"36","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: a retrospective study. Chin. J. Cancer Res. 36, 78\u201389 (2024).","journal-title":"Chin. J. Cancer Res."},{"key":"3037_CR9","doi-asserted-by":"crossref","unstructured":"Nakayama, I. et al. Claudin 18.2 as a novel therapeutic target. Nat. Rev. Clin. Oncol. 21, 354\u2013369 (2024).","DOI":"10.1038\/s41571-024-00874-2"},{"key":"3037_CR10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","volume":"30","author":"O T\u00fcreci","year":"2019","unstructured":"T\u00fcreci, O. et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann. Oncol. 30, 1487\u20131495 (2019).","journal-title":"Ann. Oncol."},{"key":"3037_CR11","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1200\/JCO.2023.41.16_suppl.4035","volume":"41","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG\/GEJ) adenocarcinoma: biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). J. Clin. Oncol. 41, 4035 (2023).","journal-title":"J. Clin. Oncol."},{"key":"3037_CR12","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","volume":"29","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133\u20132141 (2023).","journal-title":"Nat. Med."},{"key":"3037_CR13","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655\u20131668 (2023).","journal-title":"Lancet"},{"key":"3037_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"3037_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02314","author":"C Qi","year":"2024","unstructured":"Qi, C. et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: a pooled analysis of two early-phase trials. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.23.02314 (2024).","journal-title":"J. Clin. Oncol."},{"key":"3037_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"3037_CR17","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li, J. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34, 1448\u20131454 (2016).","journal-title":"J. Clin. Oncol."},{"key":"3037_CR18","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 2461\u20132471 (2017).","journal-title":"Lancet"},{"key":"3037_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1182\/blood.2022018905","volume":"143","author":"RL Sakemura","year":"2024","unstructured":"Sakemura, R. L. et al. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood 143, 258\u2013271 (2024).","journal-title":"Blood"},{"key":"3037_CR20","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","volume":"132","author":"CA Jacobson","year":"2018","unstructured":"Jacobson, C. A. et al. End of phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma. Blood 132, 4192\u20134192 (2018).","journal-title":"Blood"},{"key":"3037_CR21","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"3037_CR22","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey, A. et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 25, 2214\u20132224 (2017).","journal-title":"Mol. Ther."},{"key":"3037_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/bloodadvances.2023011287","volume":"8","author":"AV Hirayama","year":"2024","unstructured":"Hirayama, A. V. et al. Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 8, 453\u2013467 (2024).","journal-title":"Blood Adv."},{"key":"3037_CR24","doi-asserted-by":"publisher","first-page":"eabn2231","DOI":"10.1126\/scitranslmed.abn2231","volume":"14","author":"L Evgin","year":"2022","unstructured":"Evgin, L. et al. Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci. Transl. Med. 14, eabn2231 (2022).","journal-title":"Sci. Transl. Med."},{"key":"3037_CR25","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"3037_CR26","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148\u20133165 (2023).","journal-title":"Cell"},{"key":"3037_CR27","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s43018-023-00623-x","volume":"4","author":"S Bobisse","year":"2023","unstructured":"Bobisse, S. et al. A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer. Nat. Cancer 4, 1410\u20131417 (2023).","journal-title":"Nat. Cancer"},{"key":"3037_CR28","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino, A. et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J. Pers. Med. 11, 1095 (2021).","journal-title":"J. Pers. Med."},{"key":"3037_CR29","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1007\/s00259-023-06234-z","volume":"50","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. Eur. J. Nucl. Med. Mol. Imaging 50, 2802\u20132817 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"3037_CR30","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"3037_CR31","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386, 640\u2013654 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3037_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386, 629\u2013639 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3037_CR33","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3037_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3037_CR35","doi-asserted-by":"publisher","first-page":"eade2526","DOI":"10.1126\/sciadv.ade2526","volume":"9","author":"U Uslu","year":"2023","unstructured":"Uslu, U. et al. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. Sci. Adv. 9, eade2526 (2023).","journal-title":"Sci. Adv."},{"key":"3037_CR36","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.21.02558","volume":"40","author":"X Lin","year":"2022","unstructured":"Lin, X., Lee, S., Sharma, P., George, B. & Scott, J. Summary of US Food and Drug Administration chimeric antigen receptor (CAR) T-cell biologics license application approvals from a statistical perspective. J. Clin. Oncol. 40, 3501\u20133509 (2022).","journal-title":"J. Clin. Oncol."},{"key":"3037_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam, A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387, 545\u2013557 (2016).","journal-title":"Lancet"},{"key":"3037_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial. Nat. Med. 30, 772\u2013784 (2024).","journal-title":"Nat. Med."},{"key":"3037_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29, 422\u2013429 (2023).","journal-title":"Nat. Med."},{"key":"3037_CR40","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1038\/s41375-023-02039-z","volume":"37","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. An \u2018off-the-shelf\u2019 CD2 universal CAR-T therapy for T-cell malignancies. Leukemia 37, 2448\u20132456 (2023).","journal-title":"Leukemia"},{"key":"3037_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545\u2013553 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3037_CR42","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson, M. J. et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 13, 1982\u20131997 (2023).","journal-title":"Cancer Discov."},{"key":"3037_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/jnci\/djy134","volume":"111","author":"H Jiang","year":"2019","unstructured":"Jiang, H. et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J. Natl Cancer Inst. 111, 409\u2013418 (2019).","journal-title":"J. Natl Cancer Inst."},{"key":"3037_CR44","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285\u2013295 (2017).","journal-title":"Mol. Ther."},{"key":"3037_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4155\/bio-2021-0007","volume":"13","author":"B Corsaro","year":"2021","unstructured":"Corsaro, B. et al. 2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (Part 3 - Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA\/EMA Immunogenicity Guidance\/Guideline, Gene & Cell Therapy and Vaccine Assays). Bioanalysis 13, 415\u2013463 (2021).","journal-title":"Bioanalysis"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03037-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03037-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03037-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:42:50Z","timestamp":1737697370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03037-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3037"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03037-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"4 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}